Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H12N6O10S2.2Na |
| Molecular Weight | 510.367 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC([O-])=O)\C2=CSC(N)=N2)C(=O)N1S([O-])(=O)=O
InChI
InChIKey=BGGXRVPCJUKHTQ-AHCAJXDVSA-L
InChI=1S/C12H14N6O10S2.2Na/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26;;/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26);;/q;2*+1/p-2/b17-7-;;/t5-,8+;;/m1../s1
DescriptionSources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdfCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/4073864 | https://www.ncbi.nlm.nih.gov/pubmed/3065522 | https://www.ncbi.nlm.nih.gov/pubmed/3377459
Sources: http://211.103.242.133:8080/ziyuan/CDDPdf/med/base/111/%E6%8A%97%E7%94%9F%E7%B4%A0/2320.pdf
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/4073864 | https://www.ncbi.nlm.nih.gov/pubmed/3065522 | https://www.ncbi.nlm.nih.gov/pubmed/3377459
Carumonam is a monobactam antibacterial agent. It was highly active in vitro against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae and weakly active against Streptococcus pneumoniae, but it was not active against Staphylococcus aureus. The excellent activity of carumonam against Gram-negative bacteria is related to its high affinity for their penicillin-binding proteins. It is indicated for the treatment of urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. Another factor that contributes to the excellent activity of carumonam against Gram-negative bacteria is its resistance to beta-lactamases. Adverse effects of the carumonam were limited to phlebitis at the intravenous infusion site; bloody diarrhea.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
|||
| Curative | Amasulin Approved UseIt is indicated for the treatment of infections, caused by sensitive bacteria: urinary tract infections, chronic respiratory infections, biliary tract infections, peritonitis, sepsis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
175 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
192.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
300.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
297.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
111 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
105 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
214 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
208 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
179 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1020 mg single, intravenous dose: 1020 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
493 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
783 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1302 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
56.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
113.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
230.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
107.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PROBENECID |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
117 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
186 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
602 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1112 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
186.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
156.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
330.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
287.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
170 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
147 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
300 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
293 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1020 mg single, intravenous dose: 1020 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3729324/ |
1040 mg single, intravenous dose: 1040 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.76 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
2000 mg single, intravenous dose: 2000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.99 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: PROBENECID |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.53 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.08 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1929242/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
1 g 3 times / day multiple, intravenous dose: 1 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 3 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2745245/ |
2 g 4 times / day multiple, intravenous dose: 2 g route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.82% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6395801/ |
CARUMONAM plasma | Homo sapiens |
||
72% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3364953/ |
CARUMONAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: |
Doses
| Dose | Population | Adverse events |
|---|---|---|
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: |
|
1 g 3 times / day multiple, parenteral Studied dose Dose: 1 g, 3 times / day Route: parenteral Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C260
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9568618
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
100000084877
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL1614658
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
DTXSID1046712
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
U-111
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
C79905
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
B4J4M4939D
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
86832-68-0
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
31363
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
SUB01073MIG
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | |||
|
m3141
Created by
admin on Mon Mar 31 17:54:01 GMT 2025 , Edited by admin on Mon Mar 31 17:54:01 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD
